Updates are available Erratum dated 2020-01-09
Click to view Erratum: https://doi.org/10.15252/emmm.201911749
-
Authors
Mohlin, Sofie https://orcid.org/0000-0002-2458-3963
Hansson, Karin
Radke, Katarzyna
Martinez, Sonia https://orcid.org/0000-0003-2230-7794
Blanco‐Apiricio, Carmen
Garcia‐Ruiz, Cristian https://orcid.org/0000-0003-2914-7914
Welinder, Charlotte
Esfandyari, Javanshir
O'Neill, Michael
Pastor, Joaquin
von Stedingk, Kristoffer
Bexell, Daniel https://orcid.org/0000-0001-9426-9550
-
Funding
Funding for this research was provided by:
Swedish Research Council
Cancerfonden
Barncancerfonden
Region Skåne
Research Funds of Skåne University Hospital
Mary Bevé Foundation
Magnus Bergvalls stiftelse
Thelma Zoéga Foundation
Hans von Kantzow Foundation
Crafoord Foundation
Åke Wiberg Foundation
Jeanssons Stiftelser
Ollie och Elof Ericssons stiftelser
Berth von Kantzows stiftelse
Royal Physiographic Society of Lund
Spanish Ministry of Health and Social Policy (ADE08/90038)
Spanish Ministry of Science and Innovation (CIT‐090000‐2008‐14)
- License Information
-
More Information
Article History
Received: 12 November 2018
Revised: 4 June 2019
Accepted: 24 June 2019
First Online: 16 July 2019
Change Date: 9 January 2020
Change Type: Erratum
Change Details: An Erratum to this paper has been published:
Change Details: https://doi.org/10.15252/emmm.201911749
Conflict of interest
: Michael O'Neill is Director of Research and Development at Inflection Biosciences, who provided the IBL reagents.
